Infliximab [infliximab biosimilar 3]

DRUG3 trials

Sponsors

Pfizer

Conditions

Crohn's DiseaseErythrodermic PsoriasisPsoriasis ArthropathicaPsoriasis VulgarisPustular PsoriasisRheumatoid ArthritisUlcerative Colitis

Unknown Phase

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Psoriasis)

CompletedNCT03885089

PfizerErythrodermic Psoriasis, Psoriasis Arthropathica, Psoriasis Vulgaris +1

Start: 2019-10-21End: 2024-03-08Updated: 2025-06-19

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Rheumatoid Arthritis)

CompletedNCT03885037

PfizerRheumatoid Arthritis

Start: 2019-03-20End: 2024-11-29Updated: 2026-01-06

Infliximab Biosimilar Pfizer Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

CompletedNCT03884439

PfizerCrohn's Disease, Ulcerative Colitis

Start: 2019-03-18End: 2024-02-02Updated: 2025-03-21